Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Neostigmine Methylsulfate
Therapeutic Area : Musculoskeletal
Study Phase : Approved
Recipient : Avadel Pharmaceuticals
Deal Size : $42.0 million
Deal Type : Divestment
Avadel Sells Sterile Injectables Portfolio; will Focus on Narcolepsy
Details : Company announced the sale of its portfolio of sterile injectable drugs used in the hospital setting, including three commercial products, Bloxiverz®, Vazculep®, and Akovaz®, as well as Nouress™ o Exela Sterile Medicines LLC.
Brand Name : Bloxiverz
Molecule Type : Small molecule
Upfront Cash : $14.5 million
July 01, 2020
Lead Product(s) : Neostigmine Methylsulfate
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved
Recipient : Avadel Pharmaceuticals
Deal Size : $42.0 million
Deal Type : Divestment
LOOKING FOR A SUPPLIER?
Reset All
